Welcome to our dedicated page for Noveris Health Sciences news (Ticker: MYCOF), a resource for investors and traders seeking the latest updates and insights on Noveris Health Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Noveris Health Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Noveris Health Sciences's position in the market.
Mydecine Innovations Group (CSE: MYCO) has received Conditional Approval to migrate and uplist its common shares to the NEO Exchange, enhancing its accessibility to retail and institutional investors. The final approval hinges on meeting NEO's listing requirements. This uplisting aims to increase liquidity and visibility for Mydecine, as noted by CEO Josh Bartch. The current trading symbol 'MYCO' will remain unchanged, not affecting existing shareholders' trading capabilities.
Mydecine Innovations Group (CSE: MYCO, OTC: MYCOF) has announced a bought deal offering, filing a preliminary prospectus to raise C$15 million through the sale of 30 million units at C$0.50 each. Each unit consists of one common share and a warrant, exercisable for three years at $0.70. The offering includes an over-allotment option for an additional 4.5 million units. Funds will support clinical trials, expand the drug pipeline, and for general working capital. The offering is expected to close around February 3, 2021, pending necessary approvals.
Mydecine Innovations Group (CSE: MYCO) has appointed SHIM & Associates LLP as its new auditor, replacing MNP LLP. The change was necessitated as MNP lacked the capacity to review the Company’s interim financial statements for its bought deal offering due to a busy period. A Notice of Change of Auditor has been filed on SEDAR. The Canadian Securities Exchange has neither approved nor disapproved the contents of the news release.
Mydecine Innovations Group has requested the retraction of a press release titled “Mydecine Innovations Group Upsizes Previously Announced Bought Deal,” issued by Miller Thomson LLP.
This request is made due to the lack of prior authorization from Mydecine, indicating potential issues in communications and press management.
Miller Thomson LLP has requested the cancellation of their press release regarding a C$10 million bought deal offering by Mydecine Innovations Group. The request indicates that the press release was disseminated without the company's authorization, raising concerns about proper communication protocols.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has announced an increase in its bought deal financing, raising C$15 million by offering 30 million units at C$0.50 each, with a closing date set for February 3, 2021. Each unit consists of one common share and a warrant, exercisable at $0.70 for 36 months. An over-allotment option allows for an additional 4.5 million units, potentially increasing proceeds to C$17.25 million. Funds will be used for clinical trials, expanding intellectual property, and ongoing operations.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has announced a bought deal agreement with Canaccord Genuity to purchase 20,000,000 units at C$0.50 each, totaling gross proceeds of C$10 million. Each unit consists of one common share and one purchase warrant. There is an Over-Allotment Option for an additional 3 million units, potentially increasing total proceeds to C$11.5 million. The proceeds will fund clinical trials, intellectual property expansion, and general working capital. Closing is anticipated on February 3, 2021, pending regulatory approvals.
Mydecine Innovations Group has appointed Boustead Capital Markets to facilitate its dual listing on the London Stock Exchange (LSE). This strategic move aims to provide greater exposure to European investors, particularly in psychedelic-friendly regions. The company anticipates that trading on the LSE will enhance its visibility and strengthen its market position alongside its existing listings in Canada, the U.S., and Germany. CEO Joshua Bartch emphasized that this step aligns with their focus on shareholder value and growth.
Mydecine Innovations Group has appointed Boustead Capital Markets to facilitate its dual listing on the London Stock Exchange (LSE). This move aims to enhance investor access to Mydecine's shares in Europe, especially in countries supportive of psychedelics. The LSE listing is expected to strengthen Mydecine's position in the market and provide opportunities for expansion, including clinical trials and telehealth services via Mindleap Health. The company's CEO emphasizes the strategic importance of the LSE for increasing shareholder value and investor reach.
NeuroPharm, a subsidiary of Mydecine Innovations Group (CSE: MYCO, OTC: MYCOF), has partnered with FreeMind Group to explore global non-dilutive funding for its innovative mental wellness products targeting high-risk populations like veterans. This partnership aims to leverage FreeMind's expertise in securing funding, crucial for advancing NeuroPharm's psilocybin-based therapies for PTSD, depression, and other mental health issues. Additionally, the Company has settled $847,500 in debt through the issuance of common shares.